CIAM
CTOR

Caitong International Asset Management’s Citius Oncology CTOR Stock Holding History

Caitong International Asset Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 2529

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caitong International Asset Management's CTOR Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Citius Oncology (CTOR) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #2529 among its holdings.

14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • Caitong International Asset Management held 1 share of Citius Oncology worth $1 as of Q1 2026.
  • Citius Oncology was a new Caitong International Asset Management position in Q1 2026.
  • Citius Oncology made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2529 holding.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.